The "Neuroprotection Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Amid the COVID-19 crisis, the global market for Neuroprotection Therapeutics estimated at US$53.6 Billion in the year 2020, is projected to reach a revised size of US$85.1 Billion by 2027, growing at a CAGR of 6.8% over the analysis period 2020-2027.
Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$32.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Glutamate Antagonists (Anti-Excitotoxic Agents) segment is readjusted to a revised 7.1% CAGR for the next 7-year period.
The U. S. Market is Estimated at $15.8 Billion, While China is Forecast to Grow at 6.3% CAGR
The Neuroprotection Therapeutics market in the U. S. is estimated at US$15.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.8 Billion by the year 2027 trailing a CAGR of 6.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 5.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.
Apoptosis Inhibitors Segment to Record 6.5% CAGR
In the global Apoptosis Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$6.5 Billion in the year 2020 will reach a projected size of US$10.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$9.8 Billion by the year 2027.
This report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others:
Astrocyte Pharmaceuticals Inc.
Daiichi Sankyo Co., Ltd.
Dr. Reddy's Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Novartis International AG
Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Global Competitor Market Shares
Neuroprotection Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
Total Companies Profiled: 41
For more information about this report visit https://www.researchandmarkets.com/r/p8hyxi
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005614/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900